How to Dose Modify | REVLIMID® (lenalidomide) for MDS
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma | Siriraj Medical Journal
Dosing for Mantle Cell Lymphoma | REVLIMID® (lenalidomide)
REVLIMID® (lenalidomide) Dosing for Multiple Myeloma
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma | Blood Cancer Journal
REVLIMID® (lenalidomide) - Official Patient Website
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
POR | Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
REVLIMID® Dosing - REVLIMID® (lenalidomide) - MM
Dose Modifications | REVLIMID® (lenalidomide) for MCL
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity | SpringerLink
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Main
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma | Leukemia
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial - The Lancet Oncology
Continuous Low-dose Lenalidomide Found Safe in Multiple Myeloma Trial | Starton's STAR-LLD Maintained Therapeutic Levels in Healthy Volunteers | Myeloma Research News
REVLIMID® Dosing - REVLIMID® (lenalidomide) - MM
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity | SpringerLink
Lenalidomide
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study - The Lancet Haematology
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma - Biology of Blood and Marrow Transplantation
